Chemotherapy Induced Peripheral Neuropathy Treatment Market Research, 2033
The global chemotherapy induced peripheral neuropathy treatment market size was valued at $0.9 billion in 2023, and is projected to reach $1.6 billion by 2033, growing at a CAGR of 6.1% from 2024 to 2033. The major factors driving the market growth are increasing prevalence of cancer and subsequent chemotherapy treatments. As more patients undergo chemotherapy, the incidence of CIPN rises, boosting demand for effective treatments. Additionally, advancements in medical research and technology are leading to the development of novel therapies aimed at managing and alleviating chemotherapy induced peripheral neuropathy symptoms. Furthermore, growing awareness among healthcare providers and patients about the debilitating effects of chemotherapy induced peripheral neuropathy further stimulates the market for innovative treatments that can improve quality of life during and after cancer treatment
Market Introduction and Definition
Chemotherapy-induced peripheral neuropathy (CIPN) refers to a set of symptoms caused by damage to peripheral nerves as a result of chemotherapy treatments. These symptoms typically manifest as tingling, numbness, burning sensations, sensitivity to cold or touch, muscle weakness, and difficulties with balance and coordination. CIPN can affect various parts of the body, most commonly the hands and feet, but it may also involve other areas such as the arms, legs, and even the face. The severity of symptoms can vary from mild discomfort to debilitating pain that significantly impacts daily activities and quality of life. The exact mechanisms through which chemotherapy agents induce peripheral nerve damage are not fully understood but may involve direct toxicity to nerve cells, inflammation, and disruption of nerve signaling pathways. Chemotherapy drugs commonly associated with CIPN include taxanes (such as paclitaxel and docetaxel) , platinum-based drugs (like cisplatin and oxaliplatin) , vinca alkaloids (such as vincristine) , and others. The onset and duration of CIPN can vary depending on the specific chemotherapy regimen, dosage, and individual patient factors.
Key Takeaways
- The chemotherapy induced peripheral neuropathy treatment market share study covers 20 countries. The research includes a segment analysis of each country in terms of value for the projected period.
- More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major Chemotherapy Induced Peripheral Neuropathy Treatment industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
- The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives
Key Market Dynamics
According to chemotherapy induced peripheral neuropathy treatment market forecast analysis key factors driving the growth of the market are rise in prevalence of cancer, high adoption of chemo therapy for cancer treatment and growing cases of chemotherapy induced peripheral neuropathy. With cancer incidence rising due to various factors including aging populations, lifestyle changes, and environmental influences, more individuals are undergoing chemotherapy as part of their treatment regimen. While chemotherapy is crucial for combating cancer, it often leads to peripheral nerve damage and the onset of CIPN as a significant side effect. According to 2023 article by National Library of Medicine, approximately 90% of patients with ovarian cancer receive chemotherapy, and chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and severe adverse effects of this treatment. As more patients survive and live longer with cancer due to advances in early detection and treatment options, the cumulative exposure to chemotherapy increases, heightening the risk of developing chemotherapy-induced peripheral neuropathy. Furthermore, the recognition of chemotherapy-induced peripheral neuropathy as a debilitating complication of chemotherapy by healthcare providers, researchers, and patient advocacy groups has emerged as key factor driving collaborative efforts to enhance understanding and develop targeted interventions. Thus, the rise in the prevalence of cancer and growing cases of chemotherapy induced peripheral neuropathy is expected to drive the chemotherapy induced peripheral neuropathy treatment market growth.
Top 10 Cancer Type, By Prevalnce
The top ten types of cancer, listed by their prevalence, highlight a significant health burden worldwide. Breast cancer is the most common, accounting for 12.5% of cases. It is closely followed by lung cancer, which constitutes 12.2% of cases. Colorectal cancer is the third most prevalent, with 10.7% of cases. Prostate cancer, primarily affecting men, represents 7.8% of cancer diagnoses. Stomach cancer is also notable, comprising 6% of cases, while liver cancer makes up 5%. Both cervix uterine cancer and oesophageal cancer each account for 3.3% of cases, indicating a considerable impact on the global population. Thyroid and bladder cancers each have a prevalence of 3.2%. As cancer rates increase globally, there is a growing demand for effective diagnostic tools that can accurately detect and characterize suspicious lesions. Vacuum-assisted biopsy devices have emerged as an efficient diagnostic option, offering advantages over traditional biopsy methods such as core needle biopsy.
According to the chemotherapy induced peripheral neuropathy treatment market analysis increasing prevalence of cancer globally is a pivotal factor driving the demand and growth in the chemotherapy induced peripheral neuropathy treatment market size. As cancer incidence rates rise due to factors such as aging populations, lifestyle changes, and environmental factors, more individuals are undergoing chemotherapy as a cornerstone of their cancer treatment regimen. While chemotherapy is essential for combating cancer cells, it often leads to unintended side effects like peripheral neuropathy, which can result in symptoms such as tingling, numbness, pain, and muscle weakness in the extremities.
Market Segmentation
The chemotherapy induced peripheral neuropathy treatment industry is segmented into treatment, drug class, drug type, distribution channel and region. By drug class the market is divided into nerve protective therapy, anti-inflammatory therapy, neurotransmitter-based therapy, antioxidant, others. By drug type the market is divided into branded, and generic. By distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Regional/Country Market Outlook
North America dominated the chemotherapy induced peripheral neuropathy treatment market share owing to substantial research and development activities on chemotherapy induced peripheral neuropathy, a strong presence of major key players, high prevalence of cancer. However, according to the chemotherapy induced peripheral neuropathy treatment market opportunity analysis, Asia-Pacific region is expected to register significant growth in the forecast period owing to developing healthcare infrastructure, rise in prevalence of cancer, growing awareness about the side effects of the chemotherapy.
- In a 2024 article published by National Centre for Disease Informatics and Research, it was estimated that the projected cancer burden in India is expected to rise from 26.7 million DALYs (Disability-adjusted life year) in 2021 to 29.8 million in 2025.
- According to 2024 article by National Breast Cancer Foundation, Inc, in 2024, an estimated 310, 720 women and 2, 800 men will be diagnosed with invasive breast cancer.
- In an article published by European Commission, it was reported that in 2021, cancer was the second leading cause of death in the Europe, with 1.1 million deaths.
Industry Trends
- According to 2024 article by National Cancer Institute, it was estimated that around 2, 001, 140 new cases of cancer will be diagnosed in the U.S. in 2024. According to the chemotherapy induced peripheral neuropathy treatment market trends analysis the growing prevalence of cancer is exoected to drive the growth of the market.
- According to 2023 article by National Library of Medicine, prevalence of chemotherapy induced peripheral neuropathy among individuals with ovarian cancer undergoing chemotherapy ranges from 30% to 70%.
- According to 2021 article by American Cancer Society, there were close to 20 million new cases of cancer in the year 2022
Competitive Landscape
The major players operating in the chemotherapy induced peripheral neuropathy treatment industry include Alexion Pharmaceuticals, Inc, Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Amgen Inc, Sun Pharmaceuticals Industries Ltd, Amneal Pharmaceuticals LLC, Asahi Kasei Pharma Corporation. Other players in the chemotherapy induced peripheral neuropathy treatment market include Solasia Pharma K.K, and Immunepharma.com.
Key Sources Referred
- National Library of Medicine
- Ministry of Tourism, India
- American Society of Plastic Surgeons
- American Society of Aesthetic Plastic Surgeons
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chemotherapy induced peripheral neuropathy treatment market analysis from 2024 to 2033 to identify the prevailing chemotherapy induced peripheral neuropathy treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the chemotherapy induced peripheral neuropathy treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global chemotherapy induced peripheral neuropathy treatment market trends, key players, market segments, application areas, and market growth strategies.
Chemotherapy Induced Peripheral Neuropathy Treatment Market , by Drug Class Report Highlights
| Aspects | Details |
 Market Size By 2033 | USD 1.6 Billion |
 Growth Rate | CAGR of 6.1% |
 Forecast period | 2024 - 2033 |
 Report Pages | 280 |
 By Drug Class |
|
 By Drug Type |
|
 By End User |
|
 By Region |
|
The global chemotherapy induced peripheral neuropathy treatment market was valued at $0.9 billion in 2023
The market value of chemotherapy induced peripheral neuropathy treatment market is projected to reach $1.6 billion by 2033.
The forecast period for chemotherapy induced peripheral neuropathy treatment market is 2024-2033.
The base year is 2023 in chemotherapy induced peripheral neuropathy treatment market
Major key players that operate in the chemotherapy induced peripheral neuropathy treatment market are Alexion Pharmaceuticals, Inc, Sanofi, F. Hoffmann-La Roche Ltd, Abbott Laboratories, and Amgen Inc
Loading Table Of Content...
